Delving into the Latest Updates on SKL-11197 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SKL NP, SKL-NP

Target

12/15-LOX x ALOX12 x HCN channels x VDCCs

Action

inhibitors, modulators

Mechanism

12/15-LOX inhibitors(Arachidonate 15-lipoxygenase inhibitors), ALOX12 inhibitors(12-lipoxygenase inhibitors), HCN channels modulators(Hyperpolarization-activated cyclic nucleotide-gated channel modulators)

+ [1]

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetic peripheral neuropathyPain

Originator Organization

SK Biopharmaceuticals Co., Ltd.

Active Organization-

Inactive Organization

SK Life Science, Inc.

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary Objective: To evaluate the efficacy of SKL11197 for the treatment of diabetic peripheral neuropathy pain (DPN).
Secondary Objective: To evaluate the safety and tolerability of SKL11197 in subjects with painful diabetic peripheral neuropathy.
Primary Efficacy Endpoint: The primary efficacy outcome variable will be the time to exit from the double-blind phase because of inadequate pain relief.

Start Date01 Jan 2012

Sponsor / Collaborator

SK Life Science, Inc.

100 Clinical Results associated with SKL-11197

Login to view more data

100 Translational Medicine associated with SKL-11197

Login to view more data

100 Patents (Medical) associated with SKL-11197

Login to view more data

1

Literatures (Medical) associated with SKL-11197

01 Aug 2012·The Korean Journal of Physiology & PharmacologyQ4 · MEDICINE

A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons

Q4 · MEDICINE

Article

Author: Chung, Gehoon ; Jung, Sung Jun ; Kim, Hyun Jin ; Chae, Eunhee ; Kim, Tae-hyung ; Yi, Hanju ; Shin, Hyewon ; Oh, Seog Bae ; Moon, Hongsik ; Kim, Joong Soo

In this study, we determined mode of action of a novel carbamoyloxy arylalkanoyl arylpiperazine compound (SKL-NP) on hyperpolarization-activated cyclic nucleotide-gated (HCN) channel currents (I(h)) that plays important roles in neuropathic pain. In small or medium-sized dorsal root ganglion (DRG) neurons (<40 µm in diameter) exhibiting tonic firing and prominent I(h), SKL-NP inhibited I(h) and spike firings in a concentration dependent manner (IC(50)=7.85 µM). SKL-NP-induced inhibition of I(h) was blocked by pretreatment of pertussis toxin (PTX) and N-ethylmaleimide (NEM) as well as 8-Br-cAMP, a membrane permeable cAMP analogue. These results suggest that SKL-NP modulates I(h) in indirect manner by the activation of a Gi-protein coupled receptor that decreases intracellular cAMP concentration. Taken together, SKL-NP has the inhibitory effect on HCN channel currents (I(h)) in DRG neurons of rats.

100 Deals associated with SKL-11197

Login to view more data